ACD440 granted orphan drug status in the EU
Erythromelalgia treatment gains regulatory support following EMA decision
Read MoreErythromelalgia treatment gains regulatory support following EMA decision
Read MorePASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens
Read MoreQUASAR long‑term extension results highlight durable clinical and endoscopic outcomes
Read MoreMHRA authorises medicine for patients aged 12 and over with repeated flare‑ups
Read MoreFunding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
